<DOC>
	<DOCNO>NCT01231906</DOCNO>
	<brief_summary>This randomized phase III trial study combination chemotherapy see well work compare combination chemotherapy topotecan hydrochloride treat patient non-metastatic extracranial Ewing sarcoma . Drugs use chemotherapy , vincristine sulfate , doxorubicin hydrochloride , cyclophosphamide , ifosfamide , etoposide , topotecan hydrochloride , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . It yet know whether combination chemotherapy effective topotecan hydrochloride treat Ewing sarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : l. Test effect combination vincristine ( vincristine sulfate ) , cyclophosphamide , topotecan ( topotecan hydrochloride ) ( VTC ) add standard 5-drug chemotherapy interval-compressed backbone event-free overall survival child young adult Ewing sarcoma . SECONDARY OBJECTIVES : I . To evaluate initial volumetric tumor size prognostic factor event free survival ( EFS ) patient localize Ewing tumor . II . To evaluate histologic response prognostic factor EFS patient localize Ewing tumor . III . To continue evaluation biologic marker related prognosis eventual therapeutic target via encouraging concurrent enrollment Ewing sarcoma specimen-collection study . IV . To evaluate imaging response fludeoxyglucose F 18 ( FDG ) -positron emission tomography ( PET ) prognostic factor EFS . V. To evaluate effect type local therapy EFS overall survival . VI . To evaluate effect local surgical margin conjunction histologic response EFS patient localize Ewing tumor . VII . To evaluate effect local therapy modality ( surgery , radiotherapy , combination ) well type surgical reconstruction musculoskeletal complication . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : INDUCTION THERAPY : Patients receive vincristine sulfate intravenously ( IV ) day 1 week 1 , 2 , 5 , 6 , 9 , 10 ; doxorubicin hydrochloride IV day 1 2 cyclophosphamide IV 30-60 minute day 1 week 1 , 5 , 9 ; ifosfamide IV 1 hour etoposide IV 1-2 hour day 1-5 week 3 , 7 , 11 . CONSOLIDATION THERAPY : Patients receive vincristine sulfate IV day 1 week 1 , 2 , 7 , 8 , 9 , 10 , 13 , 14 , 17 , 18 , 21 , 22 ; doxorubicin hydrochloride IV day 1 2 week 1 9 ; cyclophosphamide IV 30-60 minute day 1 week 1 , 7 , 9 , 13 , 17 , 21 ; ifosfamide IV 1 hour etoposide IV 1-2 hour day 1-5 week 3 , 5 , 11 , 15 , 19 . ARM II : INDUCTION THERAPY : Patients receive vincristine sulfate IV day 1 week 1 , 2 , 5 , 6 , 9 , 10 , 11 12 ; topotecan hydrochloride IV 30 minute day 1-5 week 1 9 ; cyclophosphamide IV 15-60 minute day 1-5 week 1 9 , day 1 week 5 11 ; ifosfamide etoposide arm I ; doxorubicin hydrochloride IV day 1 2 week 5 11 . CONSOLIDATION THERAPY : Patients receive vincristine sulfate IV day 1 week 1 , 2 , 7-10 , 13-16 , 19 , 20 ; topotecan hydrochloride IV 30 minute day 1-5 week 1 , 7 , 15 ; cyclophosphamide IV 15-60 minute day 1-5 week 1 , 7 , 15 , day 1 week 9 , 13 , 19 ; ifosfamide IV 1 hour etoposide IV 1- 2 hour day 1-5 week 3 , 5 , 11 , 17 , 21 ; doxorubicin hydrochloride IV day 1 2 week 9,13 , 19 . Patients responsive stable disease undergo may undergo surgery alone week 13 lesion complete resect negative margin reasonable functional result . Patients unresectable lesion inadequate margin surgery receive radiotherapy week 1-7 . Patients bulky lesion surgically difficult site spine , skull , periacetabular pelvis , patient poor response induction chemotherapy , patient surgery would result unacceptable functional result may undergo radiotherapy alone week 1-7 consolidation therapy , surgery perform completion consolidation chemotherapy . Patients microscopic residual disease plan pre-operative radiotherapy receive additional radiotherapy . After completion study therapy , patient follow every 3 month 3 year every 6 month 2 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive , Peripheral</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Patients newly diagnose , biopsy confirm , extracranial , nonmetastatic Ewing sarcoma primitive neuroectodermal tumor ( PNET ) bone soft tissue eligible study ; note : For purpose study , chest wall tumor ipsilateral pleural effusion , ipsilateral positive pleural fluid cytology ipsilateral pleural base secondary tumor nodule consider localized disease Patients regional node involvement , base clinical suspicion confirm pathologic documentation consider nonmetastatic Patients discontinuous osseous lesion within bone consider nonmetastatic Tumors arise bony skull ( extradural ) consider extracranial Patient eligibility base diagnosis Ewing sarcoma PNET institutional pathologist No prior chemotherapy radiation therapy allow ; patient biopsy primary tumor without attempt complete partial resection ; patient still eligible unplanned excision attempt accomplished long adequate imaging obtain prior surgery Creatinine clearance radioisotope glomerular filtration rate ( GFR ) &gt; = 70mL/min/1.73 m^2 serum creatinine base age/gender follow : 1 month &lt; 6 month : 0.4 mg/dL 6 month &lt; 1 year : 0.5 mg/dL 1 &lt; 2 year : 0.6 mg/dL 2 &lt; 6 year : 0.8 mg/dL 6 &lt; 10 year : 1 mg/dL 10 &lt; 13 year : 1.2 mg/dL 13 &lt; 16 year : 1.5 mg/dL ( male ) , 1.4 mg/dL ( female ) &gt; = 16 year : 1.7 mg/dL ( male ) , 1.4 mg/dL ( female ) Total bilirubin &lt; 1.5 x upper limit normal ( ULN ) age Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) &lt; 2.5 x upper limit normal ( ULN ) age Shortening fraction &gt; = 27 % echocardiogram , ejection fraction &gt; = 50 % radionuclide angiogram Patients must evidence metastatic disease ; metastatic disease : Are lesion discontinuous primary tumor , regional lymph node share body cavity primary tumor ; doubt whether lesion metastatic , biopsy lesion take Skeletal lesion adjacent bone ( transarticular ) Contralateral pleural effusion contralateral pleural nodule Distant lymph node involvement Patients pulmonary nodule consider metastatic disease patient : Solitary nodule &gt; 0.5 cm multiple nodule &gt; 0.3 cm unless biopsied negative Ewing 's Biopsies solitary nodule = &lt; 0.5 cm multiple nodule = &lt; 0.3 cm require perform positive indicate metastatic disease Patients whose tumor arise dural intradural soft tissue cranium spine eligible Patients pathologic diagnosis Ewing sarcoma exclude Patients diagnose Ewing Sarcoma second malignant neoplasm eligible receive chemotherapy radiation treatment primary malignancy Pregnant woman enter study ; pregnancy test must obtain female patient postmenarchal ; lactate female may participate unless agree breastfeed infant ; male female reproductive potential may participate unless agree use effective contraceptive method duration study treatment All patient and/or parent legal guardian must sign write informed consent All institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human study must meet</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>